Disease Burden And Epidemiological Need
- 40.8 million individuals living with human immunodeficiency virus in 2024.
- 1.3 million new infections documented globally in 2024.
- 120,000 infants acquired infection in 2024.
- Postnatal breastfeeding period accounts for 50 percent of infant acquisitions.
- Sustainable pandemic control requires novel preventive tools beyond antiretroviral pre-exposure prophylaxis.
Biological Obstacles To Vaccine Development
| Barrier | Pathogenic Mechanism |
|---|
| Genetic diversity | Mutation rate of 3.4 x 10-5 per base creates high variability within populations. |
| Glycan shield | Dense sugar molecules mask neutralizing viral targets on envelope trimer. |
| Rapid integration | Virus stealthily attacks and inserts genetic blueprint into host immune cells. |
| Absent natural model | No documented natural clearance of infection deprives researchers of protective immunity blueprint. |
| Strategy | Immunological Mechanism |
|---|
| Germline targeting | Sequential engineered immunogens coach B-cells to produce broadly neutralizing antibodies (bnAbs) |
| Messenger RNA platforms | Delivers stabilized envelope trimers or mosaic antigens via lipid nanoparticles. |
| T-cell vaccines | Elicit cytotoxic T-lymphocyte responses using adenovirus vectors to clear intracellular pathogen. |
| Passive prophylaxis | Direct infusion of engineered broadly neutralizing antibodies with extended half-life. |
Current Trials (2025-2026)
| Candidate / Trial | Platform | Mechanism / Target |
|---|
| IAVI G002 / G003 | mRNA | Prime-boost strategy targeting VRC01-class bnAbs. |
| HVTN 302 | mRNA | Tests stabilized HIV envelope trimers (BG505 MD39.3). |
| VIR-1388 | CMV Vector | Uses Cytomegalovirus vector to induce persistent T-cell responses. |
| PrEP-Vacc | Combination | DNA vaccine + protein boost combined with oral PrEP. |
Future Directions
- Passive Immunization: Direct infusion of lab-made bnAbs (e.g., VRC01, PGT121) as an alternative to active vaccination.
- Mucosal Immunity: Developing nasal or oral vaccines to block entry at the site of infection.
- Adjuvant Innovation: Using novel chemical compounds to enhance the magnitude and duration of the T-cell and B-cell response.
